Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy (CerebroHIE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether nerve growth factor (cerebrolysin®) therapy will improve the psychomotor outcome in infants with moderate and severe hypoxic ischemic encephalopathy after hospital discharge.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypoxic-Ischemic Encephalopathy |
Drug: Cerebrolysin® |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Phase 2 Nerve Growth Factor (Cerebrolysin®) for Treatment of Neonatal Hypoxic Ischemic Encephalopathy |
- Side effects during cerebrolysin therapy (one course). [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]weekly physical , neurological examination and parents' reported fever or convulsion during cerebrolysin injection course (10 injections).
- Neurodevelopmental follow up after 6 and 9 months of cerebrolysin injection. [ Time Frame: 9 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | March 2011 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Cerebrolysin®, neuroregeneration
Injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
|
Drug: Cerebrolysin®
injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
Other Name: Nerve Growth Factor
|
Detailed Description:
Infants with perinatal history of moderate to severe Hypoxic ischemic encephalopathy HIE will receive 10 injections of cerebrolysin IM. Assessment of neurodevelopment will be done before , 3 and 6 months after therapy
Eligibility| Ages Eligible for Study: | 3 Months to 6 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
*Inclusion Criteria: Infant aged 3-6 months with perinatal history of moderate or severe HIE collected from his NICU's file. Criteria of neonatal asphyxia and encephalopathy according to the American College of Obstetricians and Gynecologist and American Academy of Pediatrics, metabolic acidosis with a cord pH of 7.0 or less or a base deficit of at least 12 mmol/L, early onset of encephalopathy, and multisystem organ dysfunction with exclusion of other possible causes for findings.
Criteria of neonatal asphyxia:
- Full term neonate more than 36 weeks of gestation
- pH of 7.0 or less or a base deficit of 16 mmol per liter or more in a sample of umbilical-cord blood or any blood during the first hour after birth.
- If, during this interval, a pH is between 7.01 and 7.15, a base deficit is between 10 and 15.9 mmol per liter, or a blood gas is not available, additional criteria are required. These includes an acute perinatal event (e.g., late or variable decelerations, cord prolapse, cord rupture, uterine rupture, maternal trauma, hemorrhage, or cardiorespiratory arrest) and either a 10-minute Apgar score of 5 or less or assisted ventilation initiates at birth and continues for at least 10 minutes.
Criteria of neonatal encephalopathy according to Sarnat and Sarnat. Presence of one or more signs in at least three of the following six categories:
- level of consciousness.
- spontaneous activity.
- posture.
- tone.
- primitive reflexes (suck or Moro.
autonomic nervous system (pupils, heart rate, or respiration). The number of moderate or severe signs determined the extent of encephalopathy; if signs were equally distributed, the designation was based on the level of consciousness.
*Exclusion Criteria:
- Severe intrauterine growth retardation.
- Congenital malformations.
- Suspected inborn error of metabolism.
- Suspected inherited neurologic disease.
- Intracranial hemorrhage
- Meningitis
Contacts and Locations| Contact: Sahar MA Hassanein, MD | 20123183943 | saharhassanein@med.asu.edu.eg |
| Egypt | |
| Children's Hospital, Faculty of Medicine, Ain Shams University | Recruiting |
| Cairo, Egypt, 11381 | |
| Contact: Mohsen El-Alfy, MD | |
| Sub-Investigator: Shayma A. Maher, MD | |
| Principal Investigator: Ghada Gad, MD | |
| Children's Hospital, Faculty of Medicine, Ain Shams University | Recruiting |
| Cairo, Egypt, 11381 | |
| Contact: Mostafa El-Hodhod, MD moshodhod@yahoo.com | |
| Principal Investigator: Sahar MA Hassanein, MD | |
| Children's Hospital, Faculty of Medicine, Ain Shams University | Recruiting |
| Cairo, Egypt, 11381 | |
| Contact saharhassanein@med.asu.edu.eg | |
| Principal Investigator: | Sahar MA Hassanein, MD | Children's Hospital, Faculty of Medicine, Ain Shams University |
More Information
Additional Information:
No publications provided
| Responsible Party: | Sahar M.A. Hassanein, MD, Professor of Pediatrics, Children's Hospital, Faculty of Medicine, Ain Shams University |
| ClinicalTrials.gov Identifier: | NCT01059461 History of Changes |
| Other Study ID Numbers: | IRB 00006379 |
| Study First Received: | January 29, 2010 |
| Last Updated: | May 5, 2013 |
| Health Authority: | Austria: Agency for Health and Food Safety |
Keywords provided by Ain Shams University:
|
Hypoxic Ischemic Encephalopathy (HIE) Perinatal Asphyxia Nerve growth factor Cerebrolysin Cerebral palsy |
Additional relevant MeSH terms:
|
Brain Ischemia Ischemia Brain Damage, Chronic Delirium Encephalitis Hepatic Encephalopathy Neurotoxicity Syndromes Hypoxia-Ischemia, Brain Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes |
Confusion Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Central Nervous System Viral Diseases Virus Diseases Central Nervous System Infections Liver Failure Hepatic Insufficiency Liver Diseases Digestive System Diseases Brain Diseases, Metabolic Metabolic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013